Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

HIV/AIDS

Preventive HIV drugs could cut new infections by a quarter

Health economic evaluation shows that providing pre-exposure prophylaxis medicines to men who have sex with men could also save the NHS £1bn in lifelong drug treatment costs.

antiretroviral prep pill combination of two anti-HIV drugs emtricitabine and tenofovir

Source: Shutterstock.com

The first study to assess the cost effectiveness of a national roll-out of PrEP has shown that up to one in four cases could be prevented at an eventual saving to the NHS of £1bn

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men (MSM) who are at high risk of HIV infection could help to prevent up to one in four cases of HIV, a study has found[1]

The study, published in the Lancet Infectious Diseases journal, estimates that providing PrEP could result in savings of up to £1bn over 80 years, because fewer men would require lifelong HIV treatment. This is the first study to assess the cost effectiveness of a national roll-out of PrEP.  

The numbers of new HIV diagnoses in MSM in the UK have been at high levels for several years, with more than 3,000 new cases per year from 2012 to 2015, and there is a need for new prevention approaches.

PrEP, which is a combination of two anti-HIV drugs (emtricitabine and tenofovir) that are taken daily or around sexual activity to reduce a person’s risk of HIV infection, has been shown to be highly effective in preventing further infections, according to the study authors.

Researchers evaluated the cost effectiveness of PrEP when taken around sexual activity — for example, taking two pills before a sexual act, then one pill a day for every day having sex without a condom, and one pill a day for two days after sex.

They estimated costs, the number of HIV infections, and associated quality of life for MSM if PrEP was introduced in April–June 2016. They compared results against projections for a scenario where PrEP would not be introduced.

Study author Valentina Cambiano, University College London (UCL), said there was “no doubt about the effectiveness of PrEP”.

“In addition to delivering a substantial health benefit, our work suggests that introduction of PrEP will ultimately lead to a saving in costs, as a result of decreased numbers of men in need of lifelong HIV treatment,” she said.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203749

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • antiretroviral prep pill combination of two anti-HIV drugs emtricitabine and tenofovir

Jobs you might like

See more jobs

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.